Kyverna Therapeutics, Inc. Earnings Per Share (Basic)
Kyverna Therapeutics, Inc. (KYTX) reported Earnings Per Share (Basic) of -$0.63 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- Kyverna Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.63.
- Kyverna Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.66.
- Kyverna Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.80.
- Kyverna Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.85.
- Kyverna Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$3.64.
- Kyverna Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$3.33.
- Kyverna Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$89.61.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.63 10-Q · filed 2026-08-11 | -$1.29 10-Q · filed 2026-08-11 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.88 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.66 10-Q · filed 2026-05-12 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.27 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.22 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$1.65 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$2.62 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.64 10-K · filed 2026-03-26 |
| 2025-09-30 | -$0.85 10-Q · filed 2025-11-12 | -$1.82 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.85 10-Q · filed 2025-11-12 | -$3.72 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.97 10-Q · filed 2026-08-11 | -$2.01 10-Q · filed 2026-08-11 | -$2.87 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.67 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$1.03 10-Q · filed 2026-05-12 | -$1.90 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.70 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.37 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2024-12-31 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$1.67 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$2.33 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$3.33 10-K · filed 2026-03-26 |
| 2024-09-30 | -$0.80 10-Q · filed 2025-11-12 | -$1.47 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$2.45 10-Q · filed 2025-11-12 | -$3.99 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.67 10-Q · filed 2025-08-12 | -$1.66 10-Q · filed 2025-08-12 | -$3.38 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$5.36 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-03-31 | -$1.12 10-Q · filed 2025-05-13 | -$3.86 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$7.47 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$11.75 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2023-12-31 | -$25.94 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$49.45 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$70.69 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$89.61 10-K · filed 2025-03-27 |
| 2023-09-30 | -$23.27 10-Q · filed 2024-11-13 | -$44.20 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$62.75 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$20.86 10-Q · filed 2024-08-12 | -$40.40 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$12.10 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |